In April 2016 the FDA granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in Europe in October of that year.
Bishii Abriil 2016 FDA waxay ogolaatay oggolaanshaha suuqgeynta sameynta kaniiniga oo ah xariiq labaad oo daaweynta kelyaha kansarka isla sidaasna waxaa lagu ansixiyay Midowga Yurub bishii Sebtember ee sanadkaas.